Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation.

Baldassari LE, Planchon SM, Bermel RA, Nakamura K, Fisher E, Feng J, Sakaie KE, Ontaneda D, Cohen JA.

Mult Scler J Exp Transl Clin. 2019 Nov 5;5(4):2055217319887198. doi: 10.1177/2055217319887198. eCollection 2019 Oct-Dec.

2.

Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting.

Baldassari LE, Feng J, Macaron G, Planchon SM, Alshehri E, Moss BP, Ontaneda D, Willis MA.

Mult Scler J Exp Transl Clin. 2019 Sep 11;5(3):2055217319875467. doi: 10.1177/2055217319875467. eCollection 2019 Jul-Sep.

3.

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N.

Lancet Neurol. 2019 Oct;18(10):973-980. doi: 10.1016/S1474-4422(19)30151-6. Epub 2019 Jul 30. Review.

PMID:
31375366
4.

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC).

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 28;6(5):e583. doi: 10.1212/NXI.0000000000000583. eCollection 2019 Sep.

5.

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Feng J, Offerman E, Lin J, Fisher E, Planchon SM, Sakaie K, Lowe M, Nakamura K, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2019 Jun 14;5(2):2055217319856035. doi: 10.1177/2055217319856035. eCollection 2019 Apr-Jun.

6.

Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis.

Planchon SM, Lingas KT, Reese Koç J, Hooper BM, Maitra B, Fox RM, Imrey PB, Drake KM, Aldred MA, Lazarus HM, Cohen JA.

Mult Scler J Exp Transl Clin. 2018 Mar 26;4(1):2055217318765288. doi: 10.1177/2055217318765288. eCollection 2018 Jan-Mar.

7.

Modulators of Redox Metabolism in Head and Neck Cancer.

Chen X, Mims J, Huang X, Singh N, Motea E, Planchon SM, Beg M, Tsang AW, Porosnicu M, Kemp ML, Boothman DA, Furdui CM.

Antioxid Redox Signal. 2018 Dec 1;29(16):1660-1690. doi: 10.1089/ars.2017.7423. Epub 2017 Dec 20. Review.

8.

CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells.

Sargent A, Bai L, Shano G, Karl M, Garrison E, Ranasinghe L, Planchon SM, Cohen J, Miller RH.

Exp Neurol. 2017 Sep;295:222-232. doi: 10.1016/j.expneurol.2017.06.013. Epub 2017 Jun 9.

9.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

10.

Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.

Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A.

Stem Cells Transl Med. 2016 Nov;5(11):1506-1514. doi: 10.5966/sctm.2015-0243. Epub 2016 Jul 11.

11.

Abrogating the induction of type 2 diabetes mellitus secondary to statin therapy.

Planchon SM.

Cardiovasc Drugs Ther. 2014 Oct;28(5):393-4. doi: 10.1007/s10557-014-6551-8. No abstract available.

PMID:
25178970
12.

Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study.

Tavee J, Rensel M, Planchon SM, Butler RS, Stone L.

Int J MS Care. 2011 Winter;13(4):163-8. doi: 10.7224/1537-2073-13.4.163.

13.

Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.

Lobo GP, Waite KA, Planchon SM, Romigh T, Nassif NT, Eng C.

Hum Mol Genet. 2009 Aug 1;18(15):2851-62. doi: 10.1093/hmg/ddp220. Epub 2009 May 20.

14.

ATP modulates PTEN subcellular localization in multiple cancer cell lines.

Lobo GP, Waite KA, Planchon SM, Romigh T, Houghton JA, Eng C.

Hum Mol Genet. 2008 Sep 15;17(18):2877-85. doi: 10.1093/hmg/ddn185. Epub 2008 Jun 25.

15.

The nuclear affairs of PTEN.

Planchon SM, Waite KA, Eng C.

J Cell Sci. 2008 Feb 1;121(Pt 3):249-53. doi: 10.1242/jcs.022459. Review.

16.

Regulation of the PTEN promoter by statins and SREBP.

Teresi RE, Planchon SM, Waite KA, Eng C.

Hum Mol Genet. 2008 Apr 1;17(7):919-28. Epub 2007 Dec 7.

PMID:
18065496
17.

Structural and functional consequences of c-N-Ras constitutively associated with intact mitochondria.

Wolfman JC, Planchon SM, Liao J, Wolfman A.

Biochim Biophys Acta. 2006 Oct;1763(10):1108-24. Epub 2006 Aug 12.

18.

Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.

Potla R, Koeck T, Wegrzyn J, Cherukuri S, Shimoda K, Baker DP, Wolfman J, Planchon SM, Esposito C, Hoit B, Dulak J, Wolfman A, Stuehr D, Larner AC.

Mol Cell Biol. 2006 Nov;26(22):8562-71. Epub 2006 Sep 18.

19.

Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms.

Liao J, Planchon SM, Wolfman JC, Wolfman A.

J Biol Chem. 2006 Oct 6;281(40):29730-8. Epub 2006 Aug 14.

20.

beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.

Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA.

Exp Cell Res. 2001 Jul 1;267(1):95-106.

PMID:
11412042
21.

Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis.

Pink JJ, Wuerzberger-Davis S, Tagliarino C, Planchon SM, Yang X, Froelich CJ, Boothman DA.

Exp Cell Res. 2000 Mar 15;255(2):144-55.

PMID:
10694431
22.

NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.

Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA.

J Biol Chem. 2000 Feb 25;275(8):5416-24.

23.

Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation.

Yang CR, Wilson-Van Patten C, Planchon SM, Wuerzberger-Davis SM, Davis TW, Cuthill S, Miyamoto S, Boothman DA.

FASEB J. 2000 Feb;14(2):379-90.

PMID:
10657994
24.

Bcl-2 protects against beta-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells.

Planchon SM, Wuerzberger-Davis SM, Pink JJ, Robertson KA, Bornmann WG, Boothman DA.

Oncol Rep. 1999 May-Jun;6(3):485-92.

PMID:
10203579
25.

Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.

Wuerzberger SM, Pink JJ, Planchon SM, Byers KL, Bornmann WG, Boothman DA.

Cancer Res. 1998 May 1;58(9):1876-85.

26.

Damage-sensing mechanisms in human cells after ionizing radiation.

Boothman DA, Burrows HL, Yang CR, Davis TW, Wuerzberger SM, Planchon SM, Odegaard E, Lewis JE, Pink J, Meyers M, Patten CW, Sharda N, Kinsella TJ.

Stem Cells. 1997;15 Suppl 2:27-42.

27.

Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.

Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA.

Cancer Res. 1995 Sep 1;55(17):3706-11.

28.
29.

IFN-gamma modulation of epithelial barrier function. Time course, reversibility, and site of cytokine binding.

Adams RB, Planchon SM, Roche JK.

J Immunol. 1993 Mar 15;150(6):2356-63.

PMID:
8450217

Supplemental Content

Loading ...
Support Center